Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc.
Your view on ALLR
Overview
What the company does, where it operates, and who runs it.
About Allarity Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas H. Jensen
- Headquarters
- 210 Broadway, Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas H. Jensen
- Headquarters
- 210 Broadway, Boston, MA, US
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.
The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Allarity Therapeutics, Inc. from FRC's valuation model, read against the market price. ALLR last traded at $0.94; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Allarity Therapeutics, Inc.. Starting points for Allarity Therapeutics, Inc.: EPS -$0.78, beta 0.57 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Allarity Therapeutics, Inc.. Allarity Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Allarity Therapeutics, Inc.. Trailing twelve-month EPS for Allarity Therapeutics, Inc. stands at -$0.78. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Analyst Ratings
- Strong Buy0
- Buy1
- Hold1
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.21 | -$0.21 | -$0.80 | -$0.86 |
| Low estimate | -$0.21 | -$0.21 | -$0.80 | -$0.86 |
| High estimate | -$0.21 | -$0.21 | -$0.80 | -$0.86 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$0.19 | -$0.21 | -$0.78 | — |
| Growth | -10.5% | +0.0% | -2.6% | — |
Revenue Estimate
| Revenue | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $25000.00 | $85.86M |
| Low estimate | $0.00 | $0.00 | $25000.00 | $85.86M |
| High estimate | $0.00 | $0.00 | $25000.00 | $85.86M |
| No. of analysts | 0 | 0 | 1 | 1 |
| Year-ago revenue | $0.00 | $320000.00 | $320000.00 | — |
| Growth | — | -100.0% | -92.2% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Allarity Therapeutics, Inc.. Allarity Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Allarity Therapeutics, Inc. valued side by side against its closest peers. Allarity Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Allarity Therapeutics, Inc. executives and directors. Shares of Allarity Therapeutics, Inc. have traded between $0.61 and $2.35 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Allarity Therapeutics, Inc.. Coverage tracks Allarity Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Allarity Therapeutics, Inc.